Comparative Pharmacology
Head-to-head clinical analysis: ANTHELIOS SX versus CAPITAL SOLEIL 15.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTHELIOS SX versus CAPITAL SOLEIL 15.
ANTHELIOS SX vs CAPITAL SOLEIL 15
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sunscreen product containing organic UV filters (e.g., avobenzone, octocrylene) that absorb UV radiation and convert it to heat, and inorganic filters (e.g., titanium dioxide, zinc oxide) that reflect/scatter UV light. Provides broad-spectrum UVA/UVB protection.
Sunscreen agent: absorbs UVB (290-320 nm) and some UVA radiation; forms a protective film on skin.
Not applicable; topical sunscreen product. Applied liberally to all exposed skin 15 minutes before sun exposure; reapply every 2 hours or after swimming/sweating.
Apply a thin layer to all exposed skin 15-30 minutes before sun exposure; reapply every 2 hours and after swimming or sweating.
None Documented
None Documented
Terminal half-life: 12 hours (range 10-14). Clinical context: permits twice-daily dosing; prolonged in renal impairment (CrCl <30 mL/min: up to 24 h).
Terminal elimination half-life: 6-8 hours; allows twice-daily dosing but prolonged in renal impairment (up to 20 hours in CrCl <30 mL/min)
Renal: 95% (glomerular filtration and active tubular secretion). Biliary/fecal: <5%. Unchanged drug: ~80% in urine.
Renal (unchanged drug and metabolites): 70%; Fecal (biliary): 30%
Category C
Category C
Sunscreen
Sunscreen